The use of proteomics to identify novel therapeutic targets for the treatment of disease
Identifieur interne : 003868 ( Main/Exploration ); précédent : 003867; suivant : 003869The use of proteomics to identify novel therapeutic targets for the treatment of disease
Auteurs : Fleur L. Moseley [Royaume-Uni] ; Katrina A. Bicknell [Royaume-Uni] ; Michael S. Marber [Royaume-Uni] ; Gavin Brooks [Royaume-Uni]Source :
- Journal of Pharmacy and Pharmacology [ 0022-3573 ] ; 2007-05.
English descriptors
- Teeft :
- Abundance proteins, Acad, Alaiya, Antibody microarrays, April, Benign, Biol, Biomarker, Biomarkers, Biotechnol, Burbaum, Burbaum tobal, Carcinoma, Cardiac, Cardiac injury, Cardiovascular, Cardiovascular disease, Cellular, Cellular effects, Chem, Clin, Complex protein mixtures, Disease development, Drug design, Drug development, Drug discovery, Drug resistance, Drug targets, Drug treatment, Early detection, Electrophoresis, First dimension, Fleur, Gene expression, Genome, Genome sequencing consortium, Gulmann, Gygi, Hagenstein, Hagenstein sewald, Heart failure, Hydrophobic proteins, Icat, Infectious diseases, Interesting proteins, Isoelectric, Isoelectric point, Kavallaris marshall, Linker, Liotta, Liquid phase isoelectric, Malignant, Marker, Mass spectrometry, Membrane proteins, Microarrays, Modification, Molecular weight, Moseley, Multidimensional, Multidimensional protein identification technology, Mycobacterium tuberculosis, Natl, Nielsen geierstanger, Ovarian cancer, Pathway, Peptide, Petricoin, Petricoin liotta, Polypeptide expression, Potential biomarkers, Potential drug, Potential novel, Proc, Prognostic, Progression, Prostate, Prostate cancer, Protein, Protein abundance, Protein activity, Protein degradation, Protein expression, Protein function, Protein identification, Protein interactions, Protein profiles, Protein sample, Protein samples, Protein spots, Protein structure, Proteome, Proteomic, Proteomic analysis, Proteomic approaches, Proteomic discovery, Proteomic studies, Proteomic study, Proteomic techniques, Proteomic technology, Proteomics, Quantification, Quantitative analysis, Reactive, Reagent, Relative abundance, Sample preparation, Second dimension, Semmes, Serum amyloid, Several aspects, Several proteins, Sewald, Side effects, Silver staining, Spectrometry, Structural proteomics, Such technology, Therapeutic targets, Throughput, Tobal, Tumour, Tyers mann, Wide range, Yeast system.
Abstract
The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post‐translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.
Url:
DOI: 10.1211/jpp.59.5.0001
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001822
- to stream Istex, to step Curation: 001822
- to stream Istex, to step Checkpoint: 001211
- to stream Main, to step Merge: 003A22
- to stream Main, to step Curation: 003868
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of proteomics to identify novel therapeutic targets for the treatment of disease</title><author><name sortKey="Moseley, Fleur L" sort="Moseley, Fleur L" uniqKey="Moseley F" first="Fleur L." last="Moseley">Fleur L. Moseley</name></author><author><name sortKey="Bicknell, Katrina A" sort="Bicknell, Katrina A" uniqKey="Bicknell K" first="Katrina A." last="Bicknell">Katrina A. Bicknell</name></author><author><name sortKey="Marber, Michael S" sort="Marber, Michael S" uniqKey="Marber M" first="Michael S." last="Marber">Michael S. Marber</name></author><author><name sortKey="Brooks, Gavin" sort="Brooks, Gavin" uniqKey="Brooks G" first="Gavin" last="Brooks">Gavin Brooks</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D21C1E6BB99D782D49056C07BF2FD3FC46053C01</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1211/jpp.59.5.0001</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-44DLZBW2-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001822</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001822</idno><idno type="wicri:Area/Istex/Curation">001822</idno><idno type="wicri:Area/Istex/Checkpoint">001211</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001211</idno><idno type="wicri:doubleKey">0022-3573:2007:Moseley F:the:use:of</idno><idno type="wicri:Area/Main/Merge">003A22</idno><idno type="wicri:Area/Main/Curation">003868</idno><idno type="wicri:Area/Main/Exploration">003868</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The use of proteomics to identify novel therapeutic targets for the treatment of disease</title><author><name sortKey="Moseley, Fleur L" sort="Moseley, Fleur L" uniqKey="Moseley F" first="Fleur L." last="Moseley">Fleur L. Moseley</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP</wicri:regionArea><wicri:noRegion>RG6 6AP</wicri:noRegion></affiliation></author><author><name sortKey="Bicknell, Katrina A" sort="Bicknell, Katrina A" uniqKey="Bicknell K" first="Katrina A." last="Bicknell">Katrina A. Bicknell</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP</wicri:regionArea><wicri:noRegion>RG6 6AP</wicri:noRegion></affiliation></author><author><name sortKey="Marber, Michael S" sort="Marber, Michael S" uniqKey="Marber M" first="Michael S." last="Marber">Michael S. Marber</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Cardiology, Kings College London, The Rayne Institute, St Thomas' Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brooks, Gavin" sort="Brooks, Gavin" uniqKey="Brooks G" first="Gavin" last="Brooks">Gavin Brooks</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP</wicri:regionArea><wicri:noRegion>RG6 6AP</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Pharmacy and Pharmacology</title><title level="j" type="alt">JOURNAL OF PHARMACY AND PHARMACOLOGY</title><idno type="ISSN">0022-3573</idno><idno type="eISSN">2042-7158</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="609">609</biblScope><biblScope unit="page" to="628">628</biblScope><biblScope unit="page-count">20</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-05">2007-05</date></imprint><idno type="ISSN">0022-3573</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3573</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abundance proteins</term><term>Acad</term><term>Alaiya</term><term>Antibody microarrays</term><term>April</term><term>Benign</term><term>Biol</term><term>Biomarker</term><term>Biomarkers</term><term>Biotechnol</term><term>Burbaum</term><term>Burbaum tobal</term><term>Carcinoma</term><term>Cardiac</term><term>Cardiac injury</term><term>Cardiovascular</term><term>Cardiovascular disease</term><term>Cellular</term><term>Cellular effects</term><term>Chem</term><term>Clin</term><term>Complex protein mixtures</term><term>Disease development</term><term>Drug design</term><term>Drug development</term><term>Drug discovery</term><term>Drug resistance</term><term>Drug targets</term><term>Drug treatment</term><term>Early detection</term><term>Electrophoresis</term><term>First dimension</term><term>Fleur</term><term>Gene expression</term><term>Genome</term><term>Genome sequencing consortium</term><term>Gulmann</term><term>Gygi</term><term>Hagenstein</term><term>Hagenstein sewald</term><term>Heart failure</term><term>Hydrophobic proteins</term><term>Icat</term><term>Infectious diseases</term><term>Interesting proteins</term><term>Isoelectric</term><term>Isoelectric point</term><term>Kavallaris marshall</term><term>Linker</term><term>Liotta</term><term>Liquid phase isoelectric</term><term>Malignant</term><term>Marker</term><term>Mass spectrometry</term><term>Membrane proteins</term><term>Microarrays</term><term>Modification</term><term>Molecular weight</term><term>Moseley</term><term>Multidimensional</term><term>Multidimensional protein identification technology</term><term>Mycobacterium tuberculosis</term><term>Natl</term><term>Nielsen geierstanger</term><term>Ovarian cancer</term><term>Pathway</term><term>Peptide</term><term>Petricoin</term><term>Petricoin liotta</term><term>Polypeptide expression</term><term>Potential biomarkers</term><term>Potential drug</term><term>Potential novel</term><term>Proc</term><term>Prognostic</term><term>Progression</term><term>Prostate</term><term>Prostate cancer</term><term>Protein</term><term>Protein abundance</term><term>Protein activity</term><term>Protein degradation</term><term>Protein expression</term><term>Protein function</term><term>Protein identification</term><term>Protein interactions</term><term>Protein profiles</term><term>Protein sample</term><term>Protein samples</term><term>Protein spots</term><term>Protein structure</term><term>Proteome</term><term>Proteomic</term><term>Proteomic analysis</term><term>Proteomic approaches</term><term>Proteomic discovery</term><term>Proteomic studies</term><term>Proteomic study</term><term>Proteomic techniques</term><term>Proteomic technology</term><term>Proteomics</term><term>Quantification</term><term>Quantitative analysis</term><term>Reactive</term><term>Reagent</term><term>Relative abundance</term><term>Sample preparation</term><term>Second dimension</term><term>Semmes</term><term>Serum amyloid</term><term>Several aspects</term><term>Several proteins</term><term>Sewald</term><term>Side effects</term><term>Silver staining</term><term>Spectrometry</term><term>Structural proteomics</term><term>Such technology</term><term>Therapeutic targets</term><term>Throughput</term><term>Tobal</term><term>Tumour</term><term>Tyers mann</term><term>Wide range</term><term>Yeast system</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post‐translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Moseley, Fleur L" sort="Moseley, Fleur L" uniqKey="Moseley F" first="Fleur L." last="Moseley">Fleur L. Moseley</name></noRegion><name sortKey="Bicknell, Katrina A" sort="Bicknell, Katrina A" uniqKey="Bicknell K" first="Katrina A." last="Bicknell">Katrina A. Bicknell</name><name sortKey="Brooks, Gavin" sort="Brooks, Gavin" uniqKey="Brooks G" first="Gavin" last="Brooks">Gavin Brooks</name><name sortKey="Brooks, Gavin" sort="Brooks, Gavin" uniqKey="Brooks G" first="Gavin" last="Brooks">Gavin Brooks</name><name sortKey="Marber, Michael S" sort="Marber, Michael S" uniqKey="Marber M" first="Michael S." last="Marber">Michael S. Marber</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003868 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003868 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D21C1E6BB99D782D49056C07BF2FD3FC46053C01
|texte= The use of proteomics to identify novel therapeutic targets for the treatment of disease
}}
| This area was generated with Dilib version V0.6.33. |  |